• Mutation; HGNC; HGNC:644; AR; Simple; p.Gly456_Gly457insGly (c.1368_1369insGGA); Zygosity=Hemizygous (PubMed=30737244).
  
• Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000160364; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (PubMed=30737244).
  

PubMed=10918212; DOI=10.1002/1096-9896(2000)9999:9999<::AID-PATH643>3.0.CO;2-W
Dahlman T., Lammerts E., Wik M., Bergstrom D., Grimelius L., Westermark K., Rubin K., Heldin N.-E.
Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis.
J. Pathol. 191:376-386(2000)

PubMed=17465858; DOI=10.1089/thy.2006.0246
Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E., Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.
Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
Thyroid 17:289-301(2007)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25365311; DOI=10.1210/jc.2014-2359; PMCID=PMC4318896
Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T., Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S., Liu L.-Z., Tan K.-T., Chang W.J., Yang H.H., Ogawa S., Koeffler H.P.
Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.
J. Clin. Endocrinol. Metab. 100:725-735(2015)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)